Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

Background: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with small cell lung cancer (SCLC). The pharmacotherapy for SCLC occasionally induces fatal acute exacerbation of comorbid IP, especially in patients with idiopathic pulmonary fibrosis (IP...

Full description

Bibliographic Details
Main Authors:	Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Tae Iwasawa, Toshihiro Misumi, Takeharu Yamanaka, Hiroaki Okamoto
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-05-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835920923431

Similar Items

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
by: Satoshi Ikeda, et al.
Published: (2020-05-01)

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604
by: Yuki Misumi, et al.
Published: (2017-05-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Torg’s ratio in normal adult nepalese population
by: Badri Rijal, et al.
Published: (2017-04-01)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
by: Masayuki Imaya, et al.
Published: (2022-05-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
by: Tricia Tay, et al.
Published: (2022-09-01)

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
by: Satoshi Ikeda, et al.
Published: (2021-08-01)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
by: Rei Kamitani, et al.
Published: (2022-11-01)

Torg ratios based on cervical lateral plain films in normal subjects
by: David Tjahjadi, et al.
Published: (2016-02-01)

Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
by: Anase S. Asom, et al.
Published: (2022-02-01)

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
by: Yoshihiro Yamamoto, et al.
Published: (2022-05-01)

Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience
by: Jérémy Baude, et al.
Published: (2024-01-01)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
by: Tomoya Fukui, et al.
Published: (2022-12-01)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
by: Ahmed Mahdy, et al.
Published: (2023-06-01)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
by: Ayako Shiono, et al.
Published: (2023-01-01)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
by: Shiyu Jiang, et al.
Published: (2021-12-01)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
by: Hidenobu Ishii, et al.
Published: (2023-01-01)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
by: Soo Han Kim, et al.
Published: (2023-03-01)

Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?
by: Satoshi Ikeda, et al.
Published: (2022-10-01)

Small-cell neuroendocrine tumor of the bladder: Unexpected long-term survival with carboplatin-etoposide therapy in a patient with metastatic stage disease
by: Eduardo J García Rico, et al.
Published: (2023-01-01)

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient
by: Zhe Huang, et al.
Published: (2023-03-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up
by: Konstantinos Tyriakidis, et al.
Published: (2021-03-01)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma
by: Hyung-Chul Park, et al.
Published: (2012-08-01)

Comparação do Índice de Torg obtido por meio de radiografia e ressonância magnética nos pacientes com mielopatia cervical espondilótica Comparación del Índice de Torg, obtenido por medio de radiografía y resonancia, en los pacientes con mielopatía espondilótica cervical Comparison of the Torg Index obtained by radiography and magnetic resonance in patients with spondylotic cervical myelopathy
by: Alexandre de Oliveira Zam, et al.
Published: (2012-01-01)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
by: Satoshi Ikeda, et al.
Published: (2019-04-01)

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
by: Reyes Bernabé, et al.
Published: (2024-01-01)

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
by: Reza Safaee, et al.
Published: (2012-07-01)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
by: Kazushige Wakuda, et al.
Published: (2023-09-01)

Gater, torg og heterotopier i byen. En kommentar til de siste års hendelser i Paris
by: Knut Rio
Published: (2023-02-01)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
by: Chunsheng Wu, et al.
Published: (2020-01-01)

Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis
by: Marek Ussowicz, et al.
Published: (2020-12-01)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
by: Satoshi Wasamoto, et al.
Published: (2023-01-01)

Treatment Results of Extracranial Malignant Germ Cell Tumor with Regimens of Cisplatin, Vinblastine, Bleomycin or Carboplatin, Etoposide, and Bleomycin with Special Emphasis on the Sites of Vagina and Testis
by: Jen-Yin Hou, et al.
Published: (2015-10-01)

Clinical development of nintedanib for advanced non-small-cell lung cancer
by: Takeda M, et al.
Published: (2015-11-01)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
by: Yue-Ya Li, et al.
Published: (2015-06-01)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
by: Satoshi Ikeda, MD, PhD, et al.
Published: (2022-06-01)

Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
by: Naho Sakamoto, et al.
Published: (2023-03-01)

Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model
by: Yoko Miura, et al.
Published: (2021-12-01)